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OBJECTIVES Our objectives were to develop a risk-stratification model addressing the importance of the
magnitude and distribution of ST segment depression in predicting long-term outcomes and
to validate the model in an analogous patient population.
BACKGROUND Although patients without ST segment elevation presenting with acute coronary syndromes
represent an increasingly frequent population admitted to coronary care units, little attention
has been paid to quantifying their ST segment abnormalities.
METHODS ST segment depression was categorized into three groups: 1) no ST segment depression; 2)
1-mm ST segment depression in two contiguous leads; and 3) ST segment depression
$2 mm in two contiguous leads. A logistic regression model was developed using Platelet
IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global
Organization Network (PARAGON-A) data to assess the prognostic value of the extent and
distribution of ST segment depression in predicting one-year mortality. The model was
validated using the non-ST segment elevation population in Global Use of Strategies To
Open occluded arteries in acute coronary syndromes (GUSTO-IIb).
RESULTS ST segment depression was the strongest predictor of one-year mortality, accounting for 35%
of the model’s predictive power. Patients with ST segment depression $2 mm were ;6 times
(odds ratio [OR] 5.73, 95% confidence interval [CI] 2.8 to 11.6) more likely to die within one
year than patients with no ST segment depression. On validation, the model showed good
discriminatory power (c-index 5 0.75). Patients with ST segment depression $2 mm in more
than one region were almost 10 times more likely to die within one year than patients with
no ST segment depression.
CONCLUSIONS These data provide new evidence supporting the powerful prognostic value of the baseline
electrocardiogram and, in particular, the magnitude and distribution of ST segment
depression in predicting unfavorable events. (J Am Coll Cardiol 2001;38:64–71) © 2001 by
the American College of Cardiology
Patients without ST segment elevation presenting with
acute coronary syndromes represent an increasingly frequent
population admitted to coronary care units. This group is a
major socioeconomic burden on the health care system. In
recent years, a large array of novel diagnostic and therapeu-
tic options has become available for such patients. These
developments have generated a high priority on establishing
an early and accurate assessment of risk coupled with timely
and prudent triage.
Previous studies have shown that ST segment depression
on the hospital admission electrocardiogram (ECG) is
associated with increased risk among such patients (1–4). A
number of these investigations have been retrospective,
observational and composed of modest sample sizes. Little
comprehensively acquired data exist to address the impor-
tance of the magnitude of ST segment depression examined
systematically in a core laboratory and its relationship to
short- and longer term outcomes.
The Platelet IIb/IIIa Antagonism for the Reduction of
Acute coronary syndrome events in a Global Organization
Network (PARAGON-A) study provided us with an op-
portunity to examine the extent and distribution of ST
segment depression and to evaluate its prognostic ability in
predicting early and one-year outcomes (5). Employing
these data, our objectives were to develop a risk-
stratification model using baseline characteristics and to
validate the model by testing it in an analogous patient
group—namely, patients with non–ST-segment elevation
who were enrolled in the Global Use of Strategies To Open
occluded arteries in acute coronary syndromes (GUSTO-
IIb) study (6).
From the *University of Alberta, Edmonton, Alberta, Canada; †Duke Clinical
Research Institute, Durham, North Carolina; ‡St. Michael’s Hospital, Toronto,
Ontario, Canada; §Cleveland Clinic Foundation, Cleveland, Ohio; and \University
Hospital Gasthuisberg, Leuven, Belgium. Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome events in a Global Organization Network
(PARAGON-A); Global Use of Strategies To Open occluded arteries in acute
coronary syndromes (GUSTO-IIb). The PARAGON-A trial was supported by
Hoffman La-Roche (Basel, Switzerland), and the GUSTO-IIb trial was supported in
part by Guidant Corporation, Redwood City, California and Ciba-Geigy, Summit,
New Jersey.
Manuscript received August 23, 2000; revised manuscript received March 21, 2001,
accepted April 2, 2001.
Journal of the American College of Cardiology Vol. 38, No. 1, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01307-9
METHODS
Patient population. This study consisted of two patient
groups: the patients in PARAGON-A and those with
non–ST segment elevation in GUSTO-IIb. The patient
population enrolled in the PARAGON-A study has been
described elsewhere (5). Briefly, 2,282 patients with chest
discomfort within the previous 12 h, associated with tran-
sient or persistent ST segment depression $0.5 mm or
T-wave inversion or transient ST segment elevation
$0.5 mm, were included. The primary end point was death
or nonfatal myocardial infarction (MI) at 30 days. One-year
follow-up status was available for 91.5% of the patients
enrolled in the study. All patients with baseline ECG data
were included in the study. The clinical characteristics and
outcomes of patients included in the study were compared
with those excluded because of either incomplete or missing
ECG data.
The GUSTO-IIb trial comparing recombinant hirudin
and heparin therapy among patients presenting with unsta-
ble angina or acute MI enrolled 8,001 patients with non-ST
segment elevation (6). Both treatment arms were combined
for this analysis. As with PARAGON-A, the primary end
point of the GUSTO-IIb study was a composite of death
and MI in the first 30 days of follow-up. The end points of
re-infarction and death were available at 6 months, and
mortality data at 12 months. One-year status was known for
94% of this patient population. For the current study,
patients with missing or incomplete baseline ECG data
were excluded from this study.
Electrocardiographic variables. All ECG data, for both
the PARAGON-A and GUSTO-IIb studies, were evalu-
ated centrally at the ECG core laboratory at the Duke
Clinical Research Institute. The 12-lead ECGs were re-
corded at a paper speed of 25 mm/s. ST segment depression
was judged to be present if the J point was depressed by
$1 mm and was followed by a horizontal or downsloping
ST segment for at least 0.08 s in one or more of the 12 leads,
except for the aVR lead.
Quantitative ST segment depression was measured at
1-mm intervals, with every fraction rounded to the nearest
whole number. Therefore, ST segment depression of
0.5 mm was rounded to 1 mm, 1.5 mm to 2 mm, and so on.
For purposes of our analysis, ST segment depression was
categorized into three groups: 1) no ST segment depression;
2) 1-mm ST segment depression in two contiguous leads;
and 3) ST segment depression $2 mm in two contiguous
leads. For patients with potentially confounding factors
affecting ECG interpretation—that is, left bundle branch
block, right bundle branch block, left ventricular hypertro-
phy or ventricular pacemakers—ST segment depression was
measured as described earlier, but this group was analyzed
separately.
In addition to examining the impact of the magnitude of
ST segment depression on long-term mortality, we inves-
tigated the role of the distribution of ST segment depression
by identifying the number of ECG regions with ST seg-
ment depression. Four regions were examined: anteroseptal
(leads V1 to V4), apical (leads V4 to V6), lateral (leads I and
aVL) and inferior (leads II, III and aVF). A particular
region was deemed to have ST segment depression if any
two contiguous leads comprising the region had ST seg-
ment depression $2 mm.
Outcomes. The relationship between ST segment status
on hospital admission and both short- and long-term
outcomes—namely, 30-day and 6-month (repeat) MI after
admission and/or death—was examined. A multivariable
model to predict mortality at one year was developed and
validated on an independent patient population.
Treatment effect. There were five treatment arms in the
PARAGON-A study: 1 and 2) low-dose lamifiban with
and without heparin; 3 and 4) high-dose lamifiban with and
without heparin; and 5) placebo and heparin. The relation-
ship between the extent of ST segment depression and
one-year mortality was examined across treatment arms to
identify differences in treatment effect.
Statistical analyses. The chi-square test for categorical
variables and the nonparametric Kruskal-Wallis test for
continuous variables were used to compare characteristics
across groups of patients. Kaplan-Meier analysis was used to
study the relationship between the magnitude of ST seg-
ment depression and one-year mortality. Survival curves
were compared using the log-rank test statistic.
A logistic regression model was developed to assess the
prognostic value of ST segment depression in predicting
one-year mortality using PARAGON-A data (7). Univariate
analyses of baseline variables (Table 1) were performed by
using a backward stepwise variable selection procedure. The
magnitude of ST segment depression (0, 1 and 2 mm) was
included as a categorical variable. The logistic regression model
developed from the PARAGON-A data base was validated on
the non-ST segment elevation GUSTO-IIb patient popula-
tion. A predicted probability of death for each GUSTO-IIb
patient was calculated using the regression coefficients from the
PARAGON-A model. The overall performance of the model
was assessed using the c-index (8).
A second model incorporating the distribution of ST
Abbreviatons and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
ECG 5 electrocardiogram or
electrocardiographic
GUSTO-IIb 5 Global Use of Strategies To Open
occluded arteries in acute coronary
syndromes
MI 5 myocardial infarction
OR 5 odds ratio
PARAGON-A 5 Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary
syndrome events in a Global
Organization Network
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segment depression (number of regions) was developed
using the PARAGON-A data. A new categorical variable
corresponding to the following groups—no ST segment
depression and 1 mm, 2 mm with one region and 2 mm
with more than one region of ST segment depression—was
created. As a final step, this model was extended to include
patients with ECG confounders. An indicator variable for
the presence of any confounder was incorporated into the
model, and interactions between ST segment status and
confounding factors were examined.
Ethics of protocol. The Institutional Review Boards of all
participating institutions reviewed and approved the proto-
cols for both the PARAGON-A and GUSTO-IIb studies.
Written, informed consent was obtained from all patients
enrolled in the two studies.
RESULTS
Of the 2,282 patients enrolled in the PARAGON-A study,
interpretable baseline ECG data were available for 1,588
patients (70%); 396 patients (17%) had ECG confounders,
and 298 (13%) had missing data. Among patients with
missing data, 126 (42%) had no baseline ECG data and 172
had technically inadequate ECG data. There were no
significant differences in age and gender between patients
with interpretable ECGs and those with missing ECG data;
however, a higher percentage of patients with missing ECG
data had diabetes and hypertension. There were no signif-
icant differences in short- and long-term outcomes between
the two groups.
Patients with ECG confounders had higher disease
Table 1. Baseline Characteristics by ST Segment Categories: PARAGON-A Study
Characteristics
No ST2
(n 5 615)
ST2 1 mm
(n 5 704)
ST2 >2 mm
(n 5 269)
p
Value
Age (yrs) 62 (53, 70) 66 (58, 73) 67 (61, 74) ,0.001
Female (%) 34.8 38.2 23.4 ,0.001
Heart rate (beats/min) 70 (60, 80) 72 (63, 80) 78 (68, 90) 0.003
Systolic BP (mm Hg) 130 (120, 145) 135 (120, 150) 140 (120, 150) 0.003
Diastolic BP (mm Hg) 80 (70, 86) 80 (70, 85) 80 (70, 90) ,0.001
Hypertension (%) 42.6 48.9 45.0 0.072
Diabetes (%) 15.1 18.2 18.2 0.284
Lipids (%) 41.1 44.2 40.9 0.459
Family history of CAD (%) 39.3 36.9 42.0 0.320
Previous MI (%) 33.0 33.7 39.0 0.196
Previous angina (%) 72.0 76.0 74.7 0.255
Previous CHF (%) 5.4 8.1 8.6 0.095
CVD (%) 4.1 4.7 5.9 0.473
Previous PTCA (%) 11.5 9.5 4.5 0.004
Previous CABG (%) 9.9 10.5 5.9 0.086
Smoking (%) 0.021
Never 35.1 40.1 36.4
Past 38.9 35.9 45.4
Current 26.0 24.0 18.2
Severe COPD (%) 2.6 2.1 1.9 0.751
Cancer (%) 2.4 2.0 1.1 0.435
PVD (%) 4.6 8.5 11.9 ,0.001
Enrollment with MI (%) 28.2 38.8 55.1 ,0.001
Data are expressed as percentages, except for age, blood pressure and heart rate, which are expressed as median values (25th, 75th
percentiles).
BP 5 blood pressure; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; CHF 5 congestive
heart failure; COPD 5 chronic obstructive pulmonary disease; CVD 5 cerebrovascular disease; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty; PVD 5 peripheral vascular disease; ST2 5 ST segment depression.
Table 2. Outcomes by ST Segment Depression Categories: PARAGON-A and GUSTO-IIb Studies
Outcome
PARAGON-A GUSTO-IIb
No ST2
(n 5 615)
ST2 1 mm
(n 5 704)
ST2 >2 mm
(n 5 269)
No ST2
(n 5 3,158)
ST2 1 mm
(n 5 1,961)
ST2 >2 mm
(n 5 1,182)
(Re) MI 30 days 6.8 11.2 14.1 4.9 6.0 8.5
(Re) MI 6 months 8.4 14.1 16.3 6.1 7.8 11.3
Death 30 days 0.7 2.8 6.3 2.0 2.7 8.3
Death 6 months 1.1 6.2 12.0 3.6 5.6 12.1
Death 1 year 2.0 7.8 13.4 4.4 6.9 14.1
Death/MI 30 days 7.2 12.1 17.1 6.5 7.8 14.6
Death/MI 6 months 9.2 16.7 23.9 8.9 11.7 19.9
Within each trial, all rates are statistically significantly different at p , 0.001. Data are presented as percentages.
MI 5 myocardial infarction; (Re) 5 repeat; ST2 5 ST segment depression.
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severity, as indicated by their increased age, incidence of
previous MI and previous coronary artery bypass graft
surgery (CABG). These patients had significantly higher
mortality compared with other patients in the study. At 30
days, the mortality rate among patients with ECG con-
founders was 6.1%, more than twice the mortality rate of
patients with interpretable ECGs (2.6%). This difference in
mortality widened to 6.1% by one year (6.5% for patients
with ECG data and 12.6% for patients with ECG con-
founders).
In Table 1, baseline and clinical characteristics of
PARAGON-A patients are presented according to ST
segment depression status. Patients with ST segment de-
pression $2 mm were older, more likely to be male and
less likely to have undergone previous percutaneous
transluminal coronary angioplasty or CABG. The risk of
peripheral vascular disease increased with increasing ST
segment depression, as did the likelihood of presenting with
MI as the index event (28% for patients with no ST segment
depression vs. 55% for patients with ST segment depression
$2 mm).
Data on adverse outcomes are presented in Table 2. At
six months, the (repeat) MI rate among PARAGON-A
patients with ST segment depression was almost twice that
of patients with no ST segment depression. Figure 1A
shows the Kaplan-Meier one-year survival curves by mag-
nitude of ST segment depression for this patient group. The
risk of adverse events substantially increased with increasing
ST segment depression, and all of the curves were statisti-
cally significantly different at p , 0.05.
Because the focus of the study was to examine the
prognostic value of the ST segment depression, the five
arms (four treatment arms and one placebo arm) in
PARAGON-A were combined. An examination of one-
year mortality by extent of ST segment depression across the
PARAGON-A treatment groups revealed no statistically
significant differences. However, this may be due to the
small sample sizes resulting from the fragmented design of
the trial.
Of 8,001 patients with non–ST segment elevation en-
rolled in GUSTO-IIb, 6,301 (79%) had interpretable base-
line ECGs, 972 (12%) had ECG confounders and 728 (9%)
had missing or incomplete baseline ECGs. As in
PARAGON-A, patients in GUSTO-IIb with ST segment
depression $2 mm were older and less likely to have
undergone a percutaneous coronary intervention or CABG
before the index hospital period; they also had higher rates
of peripheral vascular disease and MI at enrollment (62% vs.
47% of patients with 1-mm ST segment depression and
37% of patients with no ST segment depression). In
addition, patients with $2-mm ST segment depression had
higher rates of cerebrovascular disease and severe chronic
obstructive pulmonary disease.
Table 2 and Figure 1B present data on short- and
Table 3. Univariate and Multivariate Associations Between Baseline Variables and Mortality at One Year: PARAGON-A Study
Variable
Univariate Associations Multivariable Associations
OR Lower CI Upper CI p Value OR Lower CI Upper CI p Value
Age 1.08 1.05 1.10 ,0.01 1.05 1.03 1.08 ,0.01
Gender 0.98 0.64 1.50 0.93
Diastolic BP 1.00 0.98 1.02 0.88
Systolic BP 1.00 0.99 1.01 0.92
Heart rate 1.02 1.00 1.03 ,0.01
Hypertension 1.13 0.75 1.68 0.56
Diabetes 2.24 1.44 3.50 ,0.01 1.86 1.15 3.01 0.01
Hyperlipidemia 0.75 0.49 1.13 0.17
Family history of CHD 0.92 0.61 1.39 0.69
Previous MI 2.33 1.56 3.48 ,0.01 1.89 1.22 2.94 ,0.01
Previous angina 2.52 1.39 4.55 ,0.01
CVD 3.37 1.79 6.37 ,0.01 2.06 1.00 4.24 0.05
Previous PTCA 0.47 0.19 1.18 0.11 0.38 0.14 1.03 0.06
Previous CABG 0.68 0.31 1.49 0.33
Severe COPD 6.03 2.83 12.89 ,0.01 5.69 2.37 13.70 ,0.01
Cancer 0.96 0.23 4.08 0.96
PVD 3.84 2.30 6.43 ,0.01 2.14 1.21 3.80 0.01
CHF 4.77 2.88 7.89 ,0.01 2.16 1.20 3.86 0.01
Smoking 0.07
Never 1.00 Ref.
Past 0.77 0.50 1.20
Current 0.50 0.28 0.90
ST segment status ,0.01 ,0.01
0 1.00 Ref. 1.00 Ref.
1 mm 4.25 2.25 8.02 3.65 1.89 7.06
2 mm 7.75 3.97 15.15 5.73 2.82 11.64
Enrollment with MI 1.13 0.75 1.71 0.55
CI 5 confidence interval; OR 5 odds ratio; other abbreviations as in Table 1.
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long-term outcomes among GUSTO-IIb patients. Patients
with ST segment depression $2 mm had the highest
one-year mortality rate (14.1%) compared with patients
with no ST segment depression (4.4%) and 1-mm ST
segment depression (6.9%). All of the Kaplan-Meier sur-
vival curves were statistically significantly different at p ,
0.05.
Table 3 shows the univariate and multivariable associa-
tions between baseline variables and one-year mortality
among PARAGON-A patients. After controlling for other
Figure 1. Survival curves corresponding to the categories of no ST segment depression (dep), 1-mm ST segment depression and $2-mm ST segment
depression in the PARAGON-A study (A) and GUSTO-IIb (B) studies. Log-rank tests were used to compare the survival curves. All curves were
statistically significantly different at p , 0.05.
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baseline factors, the variable describing the extent of ST
segment depression was the strongest predictor of one-year
mortality. Patients with ST segment depression $2 mm
were almost six times more likely to die by one year than
patients with no ST segment depression (odds ratio [OR]
5.7, 95% confidence interval [CI] 2.8 to 11.6). Other
significant predictors of one-year mortality, in decreasing
order of importance, were age, severe chronic obstructive
pulmonary disease, previous MI, congestive heart failure,
peripheral vascular disease, diabetes, previous percutaneous
transluminal coronary angioplasty and cerebrovascular dis-
ease. The relative contribution of the different baseline
predictors is depicted in Figure 2. ST segment status
accounted for 35% of the model’s predictive power, followed
by age, which accounted for 17%. The c-statistic for the
model was 0.82, indicating that the model had a good
discriminating ability.
A predicted risk of death was calculated for each patient
in the GUSTO-IIb population by using regression coeffi-
cients from the model developed using PARAGON-A
data. The c-index for the validation model was 0.75,
indicating that the model had a reasonably good ability to
discriminate one-year mortality in an independent patient
population.
The one-year mortality rates for patients with ST seg-
ment depression $2 mm were 13.4% and 14.1% for the
PARAGON-A and GUSTO-IIb populations, respectively
(Table 3). Further stratification showed that patients with
ST segment depression $2 mm in more than one region
had significantly higher mortality than did patients with ST
segment depression $2 mm in only one region. In
PARAGON-A, 54 patients (3%) had ST segment depres-
sion $2 mm in multiple regions. The mortality rate among
these patients was 21.2%, compared with 8.5% among
patients with ST segment depression $2 mm in only one
region. Similarly, in the GUSTO-IIb study, 252 patients
(4%) with ST segment depression $2 mm in multiple
regions had a mortality rate of 20.2%, compared with 12.5%
among patients with ST segment depression $2 mm in one
region. When including the number of regions into the
PARAGON-A multivariable model, patients with ST seg-
ment depression $2mm in multiple regions were almost 10
times more likely (OR 9.2, 95% CI 4.1 to 20.5) to die than
patients with no ST segment depression.
The event rates among PARAGON-A patients with
ECG confounders, according to the extent of ST segment
depression, are presented in Table 4. Among patients with
Figure 2. Relative contribution of baseline risk factors in predicting one-year mortality (PARAGON-A data). CHF 5 congestive heart failure; COPD 5
chronic obstructive pulmonary disease; CVD 5 cerebrovascular disease; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; PVD 5 peripheral vascular disease.
Table 4. Outcomes Among Patients With Electrocardiographic
Confounders ST segment Depression Categories:
PARAGON-A Data
Outcome
No ST2
(n 5 90)
ST2
1 mm
(n 5 175)
ST2
>2 mm
(n 5 131)
(Re) MI 30 days 4.4 8.0 20.6
(Re) MI 6 months 7.1 9.4 23.6
Death 30 days 3.3 2.9 12.2
Death 6 months 5.6 6.4 19.2
Death 1 year 6.7 8.0 22.9
Death/MI 30 days 6.7 9.1 22.1
Death/MI 6 months 11.8 14.1 29.1
All rates are statistically significantly different at p , 0.001. Data are presented as
percentages.
Abbreviations as in Table 3.
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no ST segment depression and 1-mm ST segment depres-
sion, the presence of confounders did not significantly
change the rates of adverse events. However, the combina-
tion of ST segment depression $2 mm and ECG con-
founders was indicative of maximal risk (22.9% vs. 13.4%
one-year mortality rate for patients with ST segment
depression $2 mm and no ECG confounders). When
extending the PARAGON-A model to include patients
with confounders, we found that the extent and distribution
of ST segment status dominated the presence of confound-
ers in predicting one-year mortality. Therefore, patients
with ST segment depression $2 mm in more than one
region have the worst outcomes, irrespective of the presence
of confounders.
DISCUSSION
To the best of our knowledge, our study is the first to
develop and validate a model that examines the prognostic
significance of the magnitude and extent of ST segment
depression in predicting one-year mortality. Among
PARAGON-A patients with baseline ECG data and no
confounders, 704 patients (44%) had 1-mm ST segment
depression and 269 patients (17%) had ST segment depres-
sion $2 mm in two contiguous leads. Although missing
baseline ECG data on 298 patients (13%) is a possible
limitation, these patients did not differ significantly from
study patients in terms of baseline characteristics and
outcomes.
Comparison with previous studies. Quantitative assess-
ment of the extent of ST segment depression appears to be
a more sensitive marker for adverse events than dichoto-
mous assessment of the presence or absence of ST segment
depression. In a study to prospectively validate the Braun-
wauld classification for unstable angina, Calvin et al. (9)
found the presence of ST segment depression at baseline to
be an independent predictor of recurrent MI and death (OR
3.79, 95% CI 1.65 to 8.69) (10). In the PURSUIT study,
Boersma et al. (11) found investigator-determined ST
segment depression .0.5 mm to be associated with in-
creased 30-day mortality (OR 1.8, 95% CI 1.4 to 2.3). In
our logistic regression model to predict one-year mortality
using PARAGON-A data, patients with 1-mm ST seg-
ment depression in two contiguous leads were associated
with approximately four times the risk (OR 3.6, 95% CI 1.9
to 7.1), and patients with ST segment depression $2 mm
were associated with approximately six times the risk (OR
5.7, 95% CI 2.8 to 11.6) of patients with no ST segment
depression. The extent of ST segment depression accounted
for more than one-third of the model’s predictive power.
The model was tested on an independent patient population
enrolled in the GUSTO-IIb trial and showed good discrim-
inating ability (c-index 5 0.75).
Most recently, Antman et al. (12) published a risk score
to stratify patients with unstable angina/non-ST segment
elevation MI . In both univariate and multivariate analyses,
ST segment deviation was associated with an increased risk
(multivariate OR 1.4, 95% CI 1.06 to 1.85) of mortality,
(repeat) MI or severe, recurrent ischemia prompting revas-
cularization in the short term (14 days). No attempt was
made to quantify the extent of ST segment deviation. Our
findings show that ST segment depression $2 mm in two
contiguous leads may be a more effective risk stratifier for
short- and long-term mortality, as demonstrated by the
better discriminatory power of our model (c-statistic 5 0.82
vs. 0.74).
Savonitto et al. (13), using data from the GUSTO-IIb
study, examined the prognostic value of the admission ECG
in acute coronary syndromes. The 30-day rate of death/MI
was the highest for patients with a combination of ST
segment elevation and depression (12.4%, 95% CI 10.9 to
14.0), and next highest for patients with ST segment
depression (10.5%, 95% CI 9.6 to 11.5). After adjusting for
baseline factors, ECG category was a highly significant
predictor of 30-day outcomes.
Our study differs from that of Savonitto et al. (13) in
several aspects. First, our focus was the non-ST segment
elevation population, and we examined one-year mortality
as opposed to shorter term death/MI outcomes. Second,
Savonitto et al. (13) classified ST segment depression as
.0.5 mm, whereas we examined the quantitative extent of
ST segment depression, and as the data show, patients with
ST segment depression $2 mm fare far worse than patients
with less extensive ST segment depression. A third distinc-
tion relates to the source of ECG data used to classify
patients. Although our study used ECG data analyzed
systematically at a central ECG core laboratory, the previous
study used investigator-reported data, which has the poten-
tial for site-related biases.
Impact of regions and confounders. There is no docu-
mentation in the published data on the impact of the
distribution of ST segment depression (i.e., the number of
regions affected by it) on adverse events. Although our
finding—that the extent of ST segment depression (0 to
$2 mm) is positively correlated with long-term adverse
events—is consistent with previous findings (2), we found
that further stratification of the ST segment depression
$2-mm group into those with more than one region was a
better prognostic indicator of one-year mortality.
Previous studies have generally excluded patients with
confounding factors. As shown in our study, patients with
left ventricular hypertrophy, complete bundle branch block
and cardiac pacing are a substantial part of the population
(17% in PARAGON-A and 12% in GUSTO-IIb). We
have shown that the higher risk associated with the presence
of ECG confounders is further accentuated by the extent of
ST segment depression. In a multivariable setting, the
extent and distribution of ST segment depression was the
most important predictor of one-year mortality, irrespective
of the presence of confounders.
Conclusions. These data provide new evidence supporting
the powerful prognostic value of the baseline ECG and, in
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particular, the magnitude and distribution of ST segment
depression in predicting unfavorable events in both the
short and long term. The extent of ST segment depression
is an independent and important modulator of the risk of
short- and long-term death and should be incorporated into
early evaluations. Most ominous of all is the $2-mm ST
segment depression sign. The high morbidity and mortality
among these patients highlights the need for new strategies
aimed at enhanced early triage and more aggressive thera-
pies in this population.
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